These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9197356)

  • 21. Absence of irreversible rejection in the presence of warm anti-donor-HLA class I cytotoxic IgG antibody.
    Shoker A; Klassen J; Herbut B
    Clin Nephrol; 1997 Feb; 47(2):87-91. PubMed ID: 9049455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Postoperative flow cytometry crossmatch in living donor liver transplantation: clinical significance of humoral immunity in acute rejection.
    Kasahara M; Kiuchi T; Takakura K; Uryuhara K; Egawa H; Asonuma K; Uemoto S; Inomata Y; Ohwada S; Morishita Y; Tanaka K
    Transplantation; 1999 Feb; 67(4):568-75. PubMed ID: 10071029
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Specificity and Ig class of preformed alloantibodies causing a positive crossmatch in renal transplantation. The implications for graft survival.
    ten Hoor GM; Coopmans M; Allebes WA
    Transplantation; 1993 Aug; 56(2):298-304. PubMed ID: 7689256
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HLA-DR matched transfusions: development of donor-specific T- and B-cell antibodies and renal allograft outcome.
    Christiaans MH; van Hooff JP; Nieman F; van den Berg-Loonen EM
    Transplantation; 1999 Apr; 67(7):1029-35. PubMed ID: 10221489
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preferential benefit of antibody induction therapy in kidney recipients with high pretransplant frequencies of donor-reactive interferon-gamma enzyme-linked immunosorbent spots.
    Augustine JJ; Poggio ED; Heeger PS; Hricik DE
    Transplantation; 2008 Aug; 86(4):529-34. PubMed ID: 18724221
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current experience with renal transplantation across the ABO barrier.
    Nelson PW; Helling TS; Shield CF; Beck M; Bryan CF
    Am J Surg; 1992 Nov; 164(5):541-4; discussion 544-5. PubMed ID: 1443385
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytotoxic flow cytometric crossmatch in renal transplantation: a single assay to simultaneously detect antibody binding and cytotoxicity.
    Thammanichanond D; Athimang W; Paisooksantivatana K; Mongkolsuk T; Ingsathit A; Worawichawong S; Kitpoka P; Jirasiritham S; Kantachuvesiri S
    Transplant Proc; 2012 Jan; 44(1):62-5. PubMed ID: 22310580
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-glutathione S-transferase T1 antibody-mediated rejection in C4d-positive renal allograft recipients.
    Aguilera I; Alvarez-Marquez A; Gentil MA; Fernandez-Alonso J; Fijo J; Saez C; Wichmann I; Nuñez-Roldan A
    Nephrol Dial Transplant; 2008 Jul; 23(7):2393-8. PubMed ID: 18308775
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biomarkers in transplantation: Prospective, blinded measurement of predictive value for the flow cytometry crossmatch after negative antiglobulin crossmatch in kidney transplantation.
    Wen R; Wu V; Dmitrienko S; Yu A; Balshaw R; Keown PA;
    Kidney Int; 2006 Oct; 70(8):1474-81. PubMed ID: 16941026
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Donor-specific antibodies after transplantation by flow cytometry: relative change in fluorescence ratio most sensitive risk factor for graft survival.
    Christiaans MH; Overhof-de Roos R; Nieman F; van Hooff JP; van den Berg-Loonen EM
    Transplantation; 1998 Feb; 65(3):427-33. PubMed ID: 9484765
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [ABO incompatible living donor kidney transplantation: a dream come true. Experience of Hospital Clínic of Barcelona].
    Oppenheimer F; Revuelta I; Serra N; Lozano M; Gutiérrez-Dalmau A; Esforzado N; Cofán F; Ricart MJ; Torregrosa JV; Crespo M; Paredes D; Martorell J; Alcáraz A; Campistol JM
    Nefrologia; 2010; 30(1):54-63. PubMed ID: 20038970
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evidence demonstrating poor kidney graft survival when acute rejections are associated with IgG donor-specific lymphocytotoxin.
    Lobo PI; Spencer CE; Stevenson WC; Pruett TL
    Transplantation; 1995 Feb; 59(3):357-60. PubMed ID: 7871565
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Flow cytometric detection of HLA-specific antibodies as a predictor of heart allograft rejection.
    Tambur AR; Bray RA; Takemoto SK; Mancini M; Costanzo MR; Kobashigawa JA; D'Amico CL; Kanter KR; Berg A; Vega JD; Smith AL; Roggero AL; Ortegel JW; Wilmoth-Hosey L; Cecka JM; Gebel HM
    Transplantation; 2000 Oct; 70(7):1055-9. PubMed ID: 11045642
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Donor-specific IgG antibody and the chronic rejection of human renal allografts.
    Pierce JC; Kay S; Lee HM
    Surgery; 1975 Jul; 78(1):14-21. PubMed ID: 1094575
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intragraft events preceding chronic renal allograft rejection in a modified tolerance protocol.
    Shimizu A; Yamada K; Sachs DH; Colvin RB
    Kidney Int; 2000 Dec; 58(6):2546-58. PubMed ID: 11115090
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sequential analysis of donor-specific antibodies and pathological findings in acute antibody-mediated rejection in a rat renal transplantation model.
    Kohei N; Tanabe T; Horita S; Omoto K; Ishida H; Yamaguchi Y; Tanabe K
    Kidney Int; 2013 Oct; 84(4):722-32. PubMed ID: 23615506
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Living-Donor Kidney Transplant With Preformed Donor-Specific Antibodies.
    Itabashi Y; Aikawa A; Muramatsu M; Hyoudou Y; Shinoda K; Takahashi Y; Sakurabayashi K; Mizutani T; Oguchi H; Arai T; Kawamura T; Hamasaki Y; Sakai K; Shishido S
    Exp Clin Transplant; 2019 Jan; 17(Suppl 1):43-49. PubMed ID: 30777522
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pre- and Posttransplant IgA Anti-Fab Antibodies to Predict Long-term Kidney Graft Survival.
    Amirzargar MA; Amirzargar A; Basiri A; Hajilooi M; Roshanaei G; Rajabi G; Solgi G
    Transplant Proc; 2015 May; 47(4):1110-3. PubMed ID: 26036531
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action.
    Jordan SC; Quartel AW; Czer LS; Admon D; Chen G; Fishbein MC; Schwieger J; Steiner RW; Davis C; Tyan DB
    Transplantation; 1998 Sep; 66(6):800-5. PubMed ID: 9771846
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Flow cytometry-detected IgG is not a contraindication to renal transplantation: IgM may be beneficial to outcome.
    Kerman RH; Susskind B; Buyse I; Pryzbylowski P; Ruth J; Warnell S; Gruber SA; Katz S; Van Buren CT; Kahan BD
    Transplantation; 1999 Dec; 68(12):1855-8. PubMed ID: 10628764
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.